Landos Biopharma, Inc. (LABP)

NASDAQ: LABP · IEX Real-Time Price · USD
0.265
+0.005 (2.04%)
Mar 24, 2023, 4:30 PM EDT - Market closed
2.04%
Market Cap 10.67M
Revenue (ttm) n/a
Net Income (ttm) -39.28M
Shares Out 40.25M
EPS (ttm) -0.98
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 40,554
Open 0.243
Previous Close 0.260
Day's Range 0.243 - 0.277
52-Week Range 0.211 - 1.920
Beta -1.13
Analysts Sell
Price Target 2.75 (+937.74%)
Earnings Date May 10, 2023

About LABP

Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company's lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and eosinophilic esophagitis; NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1 (NOD-like), a mitochondria-associated receptor assoc... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Feb 4, 2021
Employees 46
Stock Exchange NASDAQ
Ticker Symbol LABP
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for LABP stock is "Sell." The 12-month stock price forecast is $2.75, which is an increase of 937.74% from the latest price.

Price Target
$2.75
(937.74% upside)
Analyst Consensus: Sell
Stock Forecasts

News

Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2022 Results

On Track to Initiate Phase 2 Proof-of-Concept Trial in Ulcerative Colitis for NX-13 in the Second Quarter of 2023 and Report Topline Results by the Fourth Quarter of 2024

3 days ago - GlobeNewsWire

Landos Biopharma Announces Transfer of LANCL Portfolio, including Omilancor, LABP-104 and LABP-111 to Landos' Founder

Transaction Solidifies Company's Near-Term Strategic Focus on Advancing Clinical Development of NX-13

3 weeks ago - GlobeNewsWire

Landos Biopharma Announces Acceptance of Abstract on NX-13 Phase 1b Study in Ulcerative Colitis at 18th Annual Congress of the European Crohn's and Colitis Organization

Company Remains On-Track to Initiate Phase 2 Proof-of-Concept Clinical Trial in Second Quarter of 2023 Company Remains On-Track to Initiate Phase 2 Proof-of-Concept Clinical Trial in Second Quarter of...

2 months ago - GlobeNewsWire

Landos Biopharma Provides Comprehensive Update on Clinical Development Plans

Advancing NX-13 Clinical Development for Treatment of Ulcerative Colitis

2 months ago - GlobeNewsWire

Landos Biopharma Announces $16.7 Million Private Placement Financing

NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos” or the “Company”), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients ...

2 months ago - GlobeNewsWire

Landos Biopharma Reports Third Quarter 2022 Results and Provides Business Update

On Track to Complete Comprehensive Review of Clinical Development Plans in the Coming Weeks On Track to Complete Comprehensive Review of Clinical Development Plans in the Coming Weeks

4 months ago - GlobeNewsWire

Landos Biopharma Reports Second Quarter 2022 Results and Provides Business Update

Positive Top-Line Results From NX-13 Phase 1b Trial in Ulcerative Colitis Demonstrate a Favorable Safety and Tolerability Profile Across Range of Once-Daily Oral Doses, as well as Promising Early Effi...

8 months ago - GlobeNewsWire

5 Biotech Stocks Set to Outpace Q1 Earnings Estimates

Let us take a look at some drug/biotech stocks, ANGN, APLT, BOLT, IKNA and LABP, which are poised to beat on first-quarter earnings.

Other symbols: ANGNAPLTBOLTIKNA
11 months ago - Zacks Investment Research

Landos Biopharma Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update

Continued Progress Towards Optimizing Clinical Development Plans

1 year ago - GlobeNewsWire

Landos Biopharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Enhancing Focus on High-Impact Clinical-Stage Programs to Ensure Optimal Path to Commercialization

1 year ago - GlobeNewsWire

Should You Buy Landos Biopharma (LABP) Ahead of Earnings?

Landos Biopharma (LABP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

1 year ago - Zacks Investment Research

Landos Biopharma Announces Leadership Transition

Josep Bassaganya-Riera Steps Down as Chairman, President and CEO

1 year ago - GlobeNewsWire

Landos Biopharma Announces FDA Clearance of its IND for LABP-104 for the Treatment of Rheumatoid Arthritis

Phase 1 trial is underway with topline results expected in the first half of 2022

1 year ago - GlobeNewsWire

Landos Biopharma Announces FDA Clearance of its IND for LABP-104 for the Treatment of Systemic Lupus Erythematosus

Phase 1 trial initiation expected before yearend with topline results in 1H 2022

1 year ago - GlobeNewsWire

Landos Biopharma Announces Publication in Scientific Reports of Novel Preclinical Findings Demonstrating Omilancor's Therapeutic Potential in Models of Psoriasis and Further Validating the LANCL2 Mechanism

BLACKSBURG, Va., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to discover and de...

1 year ago - GlobeNewsWire

Landos Biopharma to Collaborate on a Phase 2 Study of Omilancor in Crohn's Disease with the Icahn School of Medicine at Mount Sinai

Second Phase 2 trial of omilancor in Crohn's disease (CD), expected to initiate in 2021

1 year ago - GlobeNewsWire

Landos Biopharma to Participate in Two Upcoming Investor Conferences in September

BLACKSBURG, Va., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to develop novel ...

1 year ago - GlobeNewsWire

Landos Biopharma Announces Research Collaboration into the NLRX1 Pathway in Multiple Sclerosis with Johns Hopkins University School of Medicine

BLACKSBURG, Va., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to develop novel o...

1 year ago - GlobeNewsWire

Landos Biopharma to Participate in Upcoming Investor Events

BLACKSBURG, Va., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to develop novel o...

1 year ago - GlobeNewsWire

Landos Biopharma Reports Second Quarter 2021 Financial Results and Provides Business Updates

Following the recent positive End-of-Phase 2 meeting with the FDA, Landos initiated global pivotal  Phase 3 clinical trial site feasibility studies of omilancor in ulcerative colitis (UC)

1 year ago - GlobeNewsWire

Landos Biopharma to Present at the Raymond James Virtual Human Health Innovation Conference

BLACKSBURG, Va., June 14, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late clinical-stage biopharmaceutical company utilizing its LANCE Advanced A.I. platform to discover and dev...

1 year ago - GlobeNewsWire

Landos Biopharma Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for Omilancor in Mild-to-Moderate Active Ulcerative Colitis (UC) Patients

The FDA clears the path to initiate the PACIFY I and II global registration studies in Mild-to-Moderate Active UC patients representing the potential for a broad product label for Omilancor The FDA cl...

1 year ago - GlobeNewsWire

Landos Biopharma to Present at the Jefferies Virtual Healthcare Conference

BLACKSBURG, Va., May 25, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late clinical-stage biopharmaceutical company utilizing its LANCE A.I. platform to discover and develop novel...

1 year ago - GlobeNewsWire

Landos Biopharma Announces the Appointment of Tim M. Mayleben to its Board of Directors

BLACKSBURG, Va., May 19, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients...

2 years ago - GlobeNewsWire

Landos Biopharma, LianBio Ink Licensing Pact For Omilancor & NX-13 in Greater China

Landos Biopharma Inc (NASDAQ: LABP) and LianBio have announced an exclusive collaboration and license agreement for the development and commercialization of omilancor and NX-13 in Greater China (mainl...

2 years ago - Benzinga